Sign In
Buy AMGN
$338.22
+9.96 (+3.03%)
At Close: Jun 03, 2026
Why I Still Don't Think Amgen Is A Buy
10:56am, Wednesday, 06'th Aug 2025
Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline. MariTide, Amgen's promising obesity/diabe
Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly
10:56am, Wednesday, 06'th Aug 2025
Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.
Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript
09:48pm, Tuesday, 05'th Aug 2025
Amgen Inc. (NASDAQ:AMGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Development
Amgen (AMGN) Q2 Profit Jumps 21%
08:53pm, Tuesday, 05'th Aug 2025
Amgen (AMGN) Q2 Profit Jumps 21%
Amgen (AMGN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Tuesday, 05'th Aug 2025
While the top- and bottom-line numbers for Amgen (AMGN) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to W
Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates
06:16pm, Tuesday, 05'th Aug 2025
Amgen (AMGN) came out with quarterly earnings of $6.02 per share, beating the Zacks Consensus Estimate of $5.26 per share. This compares to earnings of $4.97 per share a year ago.
Amgen beats on Q2 revenue, slightly raises guidance
04:39pm, Tuesday, 05'th Aug 2025
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Amgen's Q2 earnings results.
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
04:01pm, Tuesday, 05'th Aug 2025
THOUSAND OAKS, Calif. , Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.
Trade Deficit Narrowed More Than Expected
12:05pm, Tuesday, 05'th Aug 2025
Pre-market futures are in the green across major indexes this morning, but experiencing a bit of choppiness. The Dow and S&P 500 are both up mere single-digits at this hour, off the early-morning high
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board
08:00am, Tuesday, 05'th Aug 2025
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
12:51pm, Monday, 04'th Aug 2025
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
Buy or Sell Amgen Stock Ahead of Its Earnings?
11:02am, Monday, 04'th Aug 2025
Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a tendency to experience negative one-day returns following its earnings announceme
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
04:01pm, Friday, 01'st Aug 2025
THOUSAND OAKS, Calif. , Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025.
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
